NCT05182359View on ClinicalTrials.gov

Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Type 2 Diabetes
Interventions
OTHER

SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test

The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.

Trial Locations (1)

44106

University Hospitals, Cleveland

All Listed Sponsors
collaborator

SomaLogic, Inc.

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER